TCAP Platform
Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's)
PreclinicalResearch
Key Facts
Indication
Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's)
Phase
Preclinical
Status
Research
Company
About Protagenic Therapeutics
Protagenic Therapeutics is a public, clinical-stage biotechnology company developing a novel class of therapeutics based on the Teneurin C-terminal Associated Peptide (TCAP) to regulate the stress response system. Founded in 2015, the company's mission is to address the root cause of stress-related disorders like depression, anxiety, PTSD, and addiction, where current treatments are often inadequate. Its strategy involves building a proprietary TCAP platform to efficiently develop multiple drug candidates for a broad spectrum of CNS indications. The lead candidate, PT00114, is advancing into clinical trials, representing a potentially transformative approach to neuronal health.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's) Drugs
| Drug | Company | Phase |
|---|---|---|
| Ocular Tracer Platform | Amydis Diagnostics | Phase 1 |
| NeurOdys Therapeutics (Portfolio Company) | Expert Systems | Pre-clinical |
| Neurodegenerative Disease Diagnostic Program | ESP Diagnostics | Pre-clinical/Assay Development |